SciELO - Scientific Electronic Library Online

 
vol.53 número4Diferencias atencionales entre el trastorno por déficit de atención aislado y asociado a neurofibromatosis tipo 1Cultural Beliefs About the Etiology of Schizophrenia and Expressed Emotion in Mexican Families índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Colombiana de Psiquiatría

versión impresa ISSN 0034-7450

Resumen

RIBERO, Oscar et al. Effectiveness of Paliperidone Palmitate on Treatment Adherence and Relapse in the Adult Schizophrenia Population: A One-Year Mirror-Image Study in a Colombian Mental Health Care Facility. rev.colomb.psiquiatr. [online]. 2024, vol.53, n.4, pp.426-434.  Epub 04-Mar-2025. ISSN 0034-7450.  https://doi.org/10.1016/j.rcp.2022.06.001.

Introduction:

The benefits of long-acting injectable antipsychotics have been documented in several observational studies, but data remain scarce in Latin America. This study aimed at evaluating the effectiveness of paliperidone palmitate once monthly (PP1M) on treatment adherence and relapse in the schizophrenia population followed in a government-funded mental health care facility in Colombia.

Methods:

A mirror-image study was conducted. Adult schizophrenia patients treated with oral antipsychotics who subsequently received ≥2 PP1M injections between Jan. 1st, 2015 and Oct. 31st, 2018 were included. The study consisted of two retrospective phases: 12 months before and after the first PP1M injection. Outcomes were treatment adherence (proportion of days covered ≥80%), hospitalized relapse, hospital length of stay, and non-hospitalised relapse. Effect of PP1M on outcomes was assessed through multivariable conditional Poisson regression.

Results:

123 patients were eligible (mean age, 30.3 years; 79.7% males). Adherence was 23.6% in the pre-phase and 89.4% in the post-phase (RR = 3.77; 95%CI, 2.75-5.17). The proportion of patients with hospitalised relapse decreased from 46.3% to 35.0% (RR = 0.76; 95%CI, 0.590.99). In the 75 (61.0%) patients who continued PP1M throughout post-phase, beneficial effect on hospitalised relapse was stronger (RR = 0.64; 95%CI, 0.42-0.98). The proportion of patients with non-hospitalised relapse symptoms increased from 6.5% to 18.7% (RR = 2.27; 95%CI, 1.11-4.64).

Conclusions:

PP1M initiation led to a dramatic improvement in treatment adherence and a decrease in hospitalised relapse. Observed increase in non-hospitalised relapse may be explained by a decrease in severity. Limitations are absence of a parallel comparison group and a generalisability limited to the population treated at this facility. Study provides data for the Latin America region and strength is the assessment of non-hospitalised relapse symptoms.

Palabras clave : Antipsychotics; Paliperidone palmitate; Schizophrenia; Adherence; Relapse.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )